The Role of Gab2 Signaling in Thromboinflammation

Gab2 信号传导在血栓炎症中的作用

基本信息

项目摘要

Inflammation is a protective response of the organism to fight against invading pathogens or endogenous danger signals such as damaged cells. However, when the response goes unchecked, it results in tissue damage and contributes to the pathogenesis of various diseases such as rheumatoid arthritis, neurodegenerative diseases, heart diseases, and stroke. Recent studies strongly indicate that Inflammatory processes play a crucial role in the pathogenesis of venous thromboembolism (VTE). Although the signaling pathways activated by the inflammatory mediators have been extensively studied, still key gaps exist in our understanding of how cells exposed to various inflammatory stimuli integrate signals from diverse receptors to activate common downstream signaling pathways to stimulate transcription factors such as NF-kB and AP-1 and induce the expression of proinflammatory cell adhesion molecules, cytokines, procoagulant clotting factors. Activation of Toll-like receptors (TLRs), tumor necrosis factor (TNF), and interleukin 1 (IL-1) receptors by their ligands triggers the formation of multi-subunit signaling complexes that include many scaffolding proteins. Gab2 (growth factor receptor-bound protein 2 (Grb2)-associated binding protein 2) is a scaffolding adapter protein that integrates and amplifies signals from a wide variety of extracellular stimuli, including growth factors, antigen receptors, and cell adhesion molecules. Gab2 is shown to play a critical role in allergy, cancer, and hematopoiesis. However, to date, the role of Gab2 in inflammatory signaling is unknown. Our preliminary studies show that Gab2 silencing attenuates TNFα-, IL-1β-, and LPS- induced expression of cell adhesion molecules, cytokines, and procoagulant cofactor, tissue factor in endothelial cells. Gab2 silencing has been found to attenuate the activation of the NF- κB and MAPKs. We hypothesize that Gab2 plays a central role in TNFR1-, IL-1R1-, and TLR4- mediated inflammatory signaling pathways in endothelial cells, and Gab2-dependent signaling contributes to the pathogenesis of VTE. In Aim 1, we will elucidate the mechanism by which Gab2 transmits TNFR1-, IL-1R1-, and TLR4-mediated signaling in endothelial cells, including the structural requirements of Gab2 in mediating TNFR1-, IL-1R1, and TLR4-mediated signal transduction and its activation of TAK1 (TGF-β-activated kinase 1), a key modulator of transcription factors NF-κB and AP-1. In Aim 2, we will determine the role of Gab2 inflammatory signaling in sepsis and the pathogenesis of VTE using Gab2-deficient mice and wild-type littermate controls. Impact: Establishing Gab2 as a crucial player in inflammatory signaling and elucidating the mechanism underlying how Gab2 integrates and transmits signals induced by different inflammatory signaling pathways would lead to new and exciting research on Gab2’s role in innate immunity and inflammation. Data from our studies will provide novel insights for designing new and effective therapies to treat inflammatory disorders.
炎症是机体对抗入侵病原体或内源性危险的一种保护性反应

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Vijaya Mohan Rao Lella其他文献

Vijaya Mohan Rao Lella的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Vijaya Mohan Rao Lella', 18)}}的其他基金

Tissue Factor's Role in the Pathogenesis of Hypercoagulability in COVID-19
组织因子在 COVID-19 高凝状态发病机制中的作用
  • 批准号:
    10448667
  • 财政年份:
    2022
  • 资助金额:
    $ 18.38万
  • 项目类别:
Tissue Factor's Role in the Pathogenesis of Hypercoagulability in COVID-19
组织因子在 COVID-19 高凝状态发病机制中的作用
  • 批准号:
    10580840
  • 财政年份:
    2022
  • 资助金额:
    $ 18.38万
  • 项目类别:
Membrane Phospholipids: The Key Regulator of Tissue Factor Encryption/Decryption
膜磷脂:组织因子加密/解密的关键调节剂
  • 批准号:
    9054915
  • 财政年份:
    2015
  • 资助金额:
    $ 18.38万
  • 项目类别:
Membrane Phospholipids: The Key Regulators of Tissue Factor Encryption/Decryption
膜磷脂:组织因子加密/解密的关键调节剂
  • 批准号:
    10153855
  • 财政年份:
    2015
  • 资助金额:
    $ 18.38万
  • 项目类别:
Membrane Phospholipids: The Key Regulators of Tissue Factor Encryption/Decryption
膜磷脂:组织因子加密/解密的关键调节剂
  • 批准号:
    10401806
  • 财政年份:
    2015
  • 资助金额:
    $ 18.38万
  • 项目类别:
Membrane Phospholipids: The Key Regulator of Tissue Factor Encryption/Decryption
膜磷脂:组织因子加密/解密的关键调节剂
  • 批准号:
    8885418
  • 财政年份:
    2015
  • 资助金额:
    $ 18.38万
  • 项目类别:
Membrane Phospholipids: The Key Regulators of Tissue Factor Encryption/Decryption
膜磷脂:组织因子加密/解密的关键调节剂
  • 批准号:
    10615732
  • 财政年份:
    2015
  • 资助金额:
    $ 18.38万
  • 项目类别:
Factor VIIa interaction with Endothelial Cell Protein C Receptor
因子 VIIa 与内皮细胞蛋白 C 受体的相互作用
  • 批准号:
    9328143
  • 财政年份:
    2012
  • 资助金额:
    $ 18.38万
  • 项目类别:
Factor VIIa Interaction with Endothelial Cell Protein C Receptor
因子 VIIa 与内皮细胞蛋白 C 受体的相互作用
  • 批准号:
    8403678
  • 财政年份:
    2012
  • 资助金额:
    $ 18.38万
  • 项目类别:
Factor VIIa Interaction with Endothelial Cell Protein C Receptor
因子 VIIa 与内皮细胞蛋白 C 受体的相互作用
  • 批准号:
    8600719
  • 财政年份:
    2012
  • 资助金额:
    $ 18.38万
  • 项目类别:

相似海外基金

Development of back bone vectors for chimeric antigen receptors against key molecules, CD47 and CD24, activating macrophages
开发针对关键分子 CD47 和 CD24 的嵌合抗原受体的骨干载体,激活巨噬细胞
  • 批准号:
    23K06728
  • 财政年份:
    2023
  • 资助金额:
    $ 18.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CAREER: Engineering next-generation chimeric antigen receptors for cancer immunotherapy using phospho-proteomics
职业:利用磷酸蛋白质组学设计用于癌症免疫治疗的下一代嵌合抗原受体
  • 批准号:
    2145853
  • 财政年份:
    2022
  • 资助金额:
    $ 18.38万
  • 项目类别:
    Continuing Grant
Construction of a drug discovery platform utilizing antigen receptors that regulate the quality of cancer immunity
利用调节癌症免疫质量的抗原受体构建药物发现平台
  • 批准号:
    22K06603
  • 财政年份:
    2022
  • 资助金额:
    $ 18.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Engineering synthetic adhesion receptors to enhance the sensitivity of therapeutic chimeric antigen receptors
工程合成粘附受体以增强治疗性嵌合抗原受体的敏感性
  • 批准号:
    MR/W031353/1
  • 财政年份:
    2022
  • 资助金额:
    $ 18.38万
  • 项目类别:
    Research Grant
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
  • 批准号:
    10701754
  • 财政年份:
    2022
  • 资助金额:
    $ 18.38万
  • 项目类别:
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
  • 批准号:
    10557760
  • 财政年份:
    2022
  • 资助金额:
    $ 18.38万
  • 项目类别:
Chimeric antigen receptors on regulatory T cells as a treatment strategy in auto-immune diseases.
调节性 T 细胞上的嵌合抗原受体作为自身免疫性疾病的治疗策略。
  • 批准号:
    437200
  • 财政年份:
    2020
  • 资助金额:
    $ 18.38万
  • 项目类别:
    Studentship Programs
Molecualr imaging for development of chimeric antigen receptors (CARs) resistant to T cell exhaustion
用于开发抗 T 细胞耗竭的嵌合抗原受体 (CAR) 的分子成像
  • 批准号:
    20H03536
  • 财政年份:
    2020
  • 资助金额:
    $ 18.38万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
  • 批准号:
    10542442
  • 财政年份:
    2020
  • 资助金额:
    $ 18.38万
  • 项目类别:
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
  • 批准号:
    9922602
  • 财政年份:
    2020
  • 资助金额:
    $ 18.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了